Ionis Pharma Stock Is Trading Lower After Roche Drops Huntington's Disease Trial With TominersenBenzinga • 03/23/21
Ionis, 3D Systems, Unity, BYD, Deere — What Cathie Wood's Ark Bought And Sold TodayBenzinga • 03/23/21
Ionis' partner provides update on clinical studies evaluating tominersen (IONIS-HTT Rx)PRNewsWire • 03/22/21
Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosisPRNewsWire • 03/01/21
Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/24/21
Ionis reports fourth quarter and full year 2020 financial results and recent business achievementsPRNewsWire • 02/24/21
Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officerPRNewsWire • 01/07/21
Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem FoundationPRNewsWire • 12/17/20
Ionis highlights achievements, commercial strategy and technology advancements at Investor DayPRNewsWire • 12/09/20
Why Is Ionis Pharmaceuticals (IONS) Up 4.6% Since Last Earnings Report?Zacks Investment Research • 12/04/20
Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conferencePRNewsWire • 12/02/20
Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndromePRNewsWire • 12/01/20
Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterolPRNewsWire • 11/30/20
Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters developmentPRNewsWire • 11/23/20
Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020PRNewsWire • 11/13/20
Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association (AHA) Scientific Sessions 2020PRNewsWire • 11/12/20
Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II ConferencePRNewsWire • 11/10/20
WAYLIVRA▼® (volanesorsen), the First and Only Therapy for Familial Chylomicronaemia Syndrome, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in ScotlandBusiness Wire • 11/09/20